Logo image of HSTO

HISTOGEN INC (HSTO) Stock Fundamental Analysis

NASDAQ:HSTO - Nasdaq - US43358Y2028 - Common Stock - Currency: USD

0.658  +0.15 (+29.27%)

After market: 0.6531 0 (-0.74%)

Fundamental Rating

3

Taking everything into account, HSTO scores 3 out of 10 in our fundamental rating. HSTO was compared to 550 industry peers in the Biotechnology industry. HSTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSTO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSTO has reported negative net income.
In the past year HSTO has reported a negative cash flow from operations.
In the past 5 years HSTO always reported negative net income.
In the past 5 years HSTO always reported negative operating cash flow.
HSTO Yearly Net Income VS EBIT VS OCF VS FCFHSTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

1.2 Ratios

HSTO's Return On Assets of -89.51% is on the low side compared to the rest of the industry. HSTO is outperformed by 75.58% of its industry peers.
HSTO has a worse Return On Equity (-130.43%) than 66.50% of its industry peers.
Industry RankSector Rank
ROA -89.51%
ROE -130.43%
ROIC N/A
ROA(3y)-79.39%
ROA(5y)-75.22%
ROE(3y)-128.82%
ROE(5y)-120.14%
ROIC(3y)N/A
ROIC(5y)N/A
HSTO Yearly ROA, ROE, ROICHSTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 19836.80%, HSTO belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
HSTO's Gross Margin has improved in the last couple of years.
HSTO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19836.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.8%
GM growth 5YN/A
HSTO Yearly Profit, Operating, Gross MarginsHSTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

HSTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSTO has been increased compared to 1 year ago.
The debt/assets ratio for HSTO has been reduced compared to a year ago.
HSTO Yearly Shares OutstandingHSTO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
HSTO Yearly Total Debt VS Total AssetsHSTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

HSTO has an Altman-Z score of -11.61. This is a bad value and indicates that HSTO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.61, HSTO is doing worse than 81.35% of the companies in the same industry.
HSTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.61
ROIC/WACCN/A
WACC9.53%
HSTO Yearly LT Debt VS Equity VS FCFHSTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

A Current Ratio of 8.54 indicates that HSTO has no problem at all paying its short term obligations.
The Current ratio of HSTO (8.54) is better than 66.67% of its industry peers.
A Quick Ratio of 8.54 indicates that HSTO has no problem at all paying its short term obligations.
HSTO has a Quick ratio of 8.54. This is in the better half of the industry: HSTO outperforms 66.83% of its industry peers.
Industry RankSector Rank
Current Ratio 8.54
Quick Ratio 8.54
HSTO Yearly Current Assets VS Current LiabilitesHSTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

HSTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.01%, which is quite impressive.
Looking at the last year, HSTO shows a very negative growth in Revenue. The Revenue has decreased by -99.56% in the last year.
HSTO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.10% yearly.
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.39%
Revenue 1Y (TTM)-99.56%
Revenue growth 3Y-30.95%
Revenue growth 5Y-36.1%
Sales Q2Q%0%

3.2 Future

HSTO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.21% yearly.
HSTO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.81% yearly.
EPS Next Y26.45%
EPS Next 2Y9.45%
EPS Next 3Y4.01%
EPS Next 5Y30.21%
Revenue Next Year-99.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y85.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HSTO Yearly Revenue VS EstimatesHSTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
HSTO Yearly EPS VS EstimatesHSTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HSTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSTO Price Earnings VS Forward Price EarningsHSTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSTO Per share dataHSTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.45%
EPS Next 3Y4.01%

More info and screens

0

5. Dividend

5.1 Amount

HSTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HISTOGEN INC

NASDAQ:HSTO (10/4/2023, 8:13:37 PM)

After market: 0.6531 0 (-0.74%)

0.658

+0.15 (+29.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners2.77%
Ins Owner Change0%
Market Cap2.81M
Analysts85.71
Price Target2.04 (210.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.07%
Min EPS beat(2)-4.49%
Max EPS beat(2)46.62%
EPS beat(4)3
Avg EPS beat(4)21.96%
Min EPS beat(4)-4.49%
Max EPS beat(4)46.62%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.9%
EPS NY rev (1m)0%
EPS NY rev (3m)30.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 147.88
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-2.92
EYN/A
EPS(NY)-2.7
Fwd EYN/A
FCF(TTM)-2.31
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0
BVpS2.18
TBVpS2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.51%
ROE -130.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19836.8%
FCFM N/A
ROA(3y)-79.39%
ROA(5y)-75.22%
ROE(3y)-128.82%
ROE(5y)-120.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.8%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.62%
Cap/Sales 52.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.54
Quick Ratio 8.54
Altman-Z -11.61
F-Score3
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)150.91%
Cap/Depr(5y)126.1%
Cap/Sales(3y)10.5%
Cap/Sales(5y)6.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.39%
EPS Next Y26.45%
EPS Next 2Y9.45%
EPS Next 3Y4.01%
EPS Next 5Y30.21%
Revenue 1Y (TTM)-99.56%
Revenue growth 3Y-30.95%
Revenue growth 5Y-36.1%
Sales Q2Q%0%
Revenue Next Year-99.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y85.81%
EBIT growth 1Y-9.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.54%
OCF growth 3YN/A
OCF growth 5YN/A